{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02478060",
      "orgStudyIdInfo": {
        "id": "CB001"
      },
      "organization": {
        "fullName": "Circassia Limited",
        "class": "INDUSTRY"
      },
      "briefTitle": "Birch-SPIRE Safety and Efficacy Study",
      "officialTitle": "A Double-Blind, Randomised, Placebo-Controlled, Escalating, Multiple Dose Study in to Assess the Safety, Tolerability and Pharmacodynamic Effects of Birch-SPIRE"
    },
    "statusModule": {
      "statusVerifiedDate": "2016-11",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2015-07"
      },
      "primaryCompletionDateStruct": {
        "date": "2016-07",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2015-06-11",
      "studyFirstSubmitQcDate": "2015-06-18",
      "studyFirstPostDateStruct": {
        "date": "2015-06-23",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2016-11-07",
      "lastUpdatePostDateStruct": {
        "date": "2016-11-08",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Circassia Limited",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "Adiga Life Sciences, Inc.",
          "class": "INDUSTRY"
        },
        {
          "name": "Quintiles, Inc.",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to evaluate the safety and tolerability of multiple administrations of Birch-SPIRE. To make a preliminary assessment on pharmacodynamic parameters and clinical outcomes."
    },
    "conditionsModule": {
      "conditions": [
        "Rhinitis"
      ],
      "keywords": [
        "Allergy",
        "Birch",
        "Rhinitis",
        "Rhinoconjuntivitis",
        "SPIRE",
        "Toleromune"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "TRIPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 64,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Cohort 1",
          "type": "EXPERIMENTAL",
          "description": "Birch-SPIRE or placebo, 2 weeks apart",
          "interventionNames": [
            "Biological: Birch-SPIRE",
            "Biological: Placebo"
          ]
        },
        {
          "label": "Cohort 2",
          "type": "EXPERIMENTAL",
          "description": "Birch-SPIRE or placebo, 2 weeks apart",
          "interventionNames": [
            "Biological: Birch-SPIRE",
            "Biological: Placebo"
          ]
        },
        {
          "label": "Cohort 3",
          "type": "EXPERIMENTAL",
          "description": "Birch-SPIRE or placebo, 2 weeks apart",
          "interventionNames": [
            "Biological: Birch-SPIRE",
            "Biological: Placebo"
          ]
        },
        {
          "label": "Cohort 4",
          "type": "EXPERIMENTAL",
          "description": "Birch-SPIRE or placebo, 2 weeks apart",
          "interventionNames": [
            "Biological: Birch-SPIRE",
            "Biological: Placebo"
          ]
        },
        {
          "label": "Cohort 5",
          "type": "EXPERIMENTAL",
          "description": "Birch-SPIRE or placebo, 2 weeks apart",
          "interventionNames": [
            "Biological: Birch-SPIRE",
            "Biological: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Birch-SPIRE",
          "armGroupLabels": [
            "Cohort 1",
            "Cohort 2",
            "Cohort 3",
            "Cohort 4",
            "Cohort 5"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Placebo",
          "armGroupLabels": [
            "Cohort 1",
            "Cohort 2",
            "Cohort 3",
            "Cohort 4",
            "Cohort 5"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Safety of Birch-SPIRE administrations measured by Adverse Events",
          "timeFrame": "Up to 16 weeks after start of dosing"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Measurement of IgE as a Pharmacodynamic parameter",
          "timeFrame": "Up to 9 months after start of dosing"
        },
        {
          "measure": "Conjunctival Provocation Test as a Pharmacodynamic parameter",
          "timeFrame": "Up to 9 months after start of dosing"
        },
        {
          "measure": "Skin Prick Testing as a Pharmacodynamic parameter",
          "timeFrame": "Up to 9 months after start of dosing"
        }
      ],
      "otherOutcomes": [
        {
          "measure": "Allergy symptoms and allergy medication use during next Birch season",
          "timeFrame": "Up to 9 months after start of dosing"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, aged 18 to 65 years;\n* Minimum 1 year history of rhinitis with or without conjunctivitis on exposure to birch pollen\n* Birch IgE ≥ 0.35 kU/L\n* Positive skin prick test to whole birch allergen\n\nExclusion Criteria:\n\n* Any past history of asthma\n* FEV1 \\< 80% of predicted\n* History of severe allergic reaction to birch allergen, severe drug allergy, severe angioedema or severe allergic reactions to food\n* Acute phase skin response to whole birch allergen with a mean wheal diameter \\> 50mm\n* Administration of adrenaline (epinephrine) is contraindicated\n* History of severe drug allergy or anaphylactic reaction to food.\n* History of any significant disease or disorder (e.g. immune system, pulmonary, cardiovascular, gastrointestinal, liver, renal, neurological, metabolic, malignant, psychiatric, major physical impairment, history of alcohol or drug abuse)",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "65 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Centre de Recherche Appliqué en Allergie de Québec",
          "city": "Québec",
          "state": "Quebec",
          "zip": "G1V 4M6",
          "country": "Canada",
          "geoPoint": {
            "lat": 46.81228,
            "lon": -71.21454
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D012220",
          "term": "Rhinitis"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        }
      ],
      "ancestors": [
        {
          "id": "D012141",
          "term": "Respiratory Tract Infections"
        },
        {
          "id": "D007239",
          "term": "Infections"
        },
        {
          "id": "D009668",
          "term": "Nose Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}